US.AMGN · Amgen

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.538752449081879,
        "turnoverUsdM": 940.0887715,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.8,
    "stopLevels": {
      "symbol": "US.AMGN",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 416.6528,
      "strength_details": {
        "ma_score": 3,
        "atr_score": 2,
        "rsi_score": 2,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.7,
      "stop_loss_percent": 5.1,
      "take_profit_price": 475.7139,
      "target_multiplier": 2.2,
      "technical_strength": 2.25,
      "take_profit_percent": 8.4
    },
    "positionPoints": 1.6,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.654355863455257,
    "stopLossPercent": 5.077504898163758,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 78.6,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 60.6,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 18
  },
  "market": {
    "ma20": 416.411,
    "ma50": 415.7288,
    "close": 438.94,
    "prevClose": 424.94,
    "avgVolume20": 2739991,
    "volumeRatio": 0.78,
    "changePercent": 3.29
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 18,
    "details": {
      "ret_5d": 0.0632206181571553,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 18,
      "vcp_bonus": 0,
      "vol_ratio": 0.7597679253047266,
      "ret_points": 12,
      "vol_points": 0,
      "range_ratio": 1.3260294791996905,
      "volat_points": 2,
      "day_range_pct": 0.03175832232195745,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 4,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 78.6,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.6,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 92,
        "contribution": 4.6
      },
      {
        "raw": 13.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 66,
        "contribution": 13.2
      },
      {
        "raw": 7.4,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 49.33,
        "contribution": 7.4
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.2,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 72,
        "contribution": 7.2
      },
      {
        "raw": 23.2,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 77.33,
        "contribution": 23.2
      },
      {
        "raw": 3,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 30,
        "contribution": 3
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 60.6,
    "details": [
      "基本面分析總分: 4.6/5分",
      "資金流分析總分: 13.2/20分",
      "市場環境分析總分: 7.4/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.2/10分",
      "技術信號分析總分: 23.2/30分",
      "情緒分析: 3/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4.6,
      "資金流": 13.2,
      "市場環境": 7.4,
      "情緒分析": 3,
      "技術信號": 23.2,
      "風險管理": 7.2
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.3,
          "marginPoints": 0.6,
          "turnoverUsdM": 940.0887715,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 1.6,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.AMGN",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 18.44
            }
          },
          "trend": {
            "score": 1.7999999999999998,
            "details": {
              "qqq": {
                "ma20": 739.87200315,
                "ma50": 726.61519988,
                "name": "QQQ",
                "close": 717.63,
                "points": 0.4
              },
              "spy": {
                "ma20": 770.61649505,
                "ma50": 768.28659516,
                "name": "SPY",
                "close": 769.049988,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.538752449081879,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 1.8,
          "marketTrendPoints": 1.7999999999999998
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 3,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 1,
              "sentimentScoreRaw": 0.3
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 143006755,
                "url": "https://finnhub.io/api/news?id=795ea8d2ea00aecba4daf0b89a83a34013816f2d050c01814823b10699d27ea5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
                "category": "company",
                "datetime": 1792411203,
                "headline": "Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 142923009,
                "url": "https://finnhub.io/api/news?id=00c6c29cc16d7b03ff19880b96b7b8fa827700084fa24fe072030ad3a300a5ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The latest trading day saw Amgen (AMGN) settling at $434.03, representing a +1.86% change from its previous close.",
                "category": "company",
                "datetime": 1792097402,
                "headline": "Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider"
              },
              {
                "id": 142920416,
                "url": "https://finnhub.io/api/news?id=e1edfeb2d3d1b855f41641b69760edc6c7630a45db8b820a950c2052acbfe992",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen and Merck both yield around 2.3% and have surged this year, but one of them is paying its dividend out of thin air while the other has a cash cushion that changes the entire income calculus.",
                "category": "company",
                "datetime": 1792082725,
                "headline": "AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow"
              },
              {
                "id": 142885266,
                "url": "https://finnhub.io/api/news?id=6ade8008a6f739f7549d16f6ca34b85649df002f32fe2e84eadb492e54b9552c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Why Amgen Stock Is Back In Focus Amgen (AMGN) moved into the spotlight after its share price climbed sharply alongside growing attention on treatments for age related conditions in the U.S., putting its role in an aging society under closer investor scrutiny. Over the past few months, momentum around Amgen has picked up, with a 30 day share price return of 9.41% and a 90 day move of 15.22% helping lift the stock to US$412.84. The 1 year total shareholder return of 44.39% and 5 year total...",
                "category": "company",
                "datetime": 1791991532,
                "headline": "Amgen (AMGN) Gains Attention On Aging Treatments, Is The Upside Already Priced In?"
              },
              {
                "id": 142885264,
                "url": "https://finnhub.io/api/news?id=ed9c9f739ded06f1de88c23820514a376159b3ea00f6238c78d47911212f309d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NasdaqGS:AMGN) and AstraZeneca reported positive Phase 3 results for Tezspire in eosinophilic esophagitis on 14 October 2026. In the trial, nearly 70% of patients receiving the higher Tezspire dose achieved remission at week 24. The study targeted eosinophilic esophagitis, a chronic inflammatory condition that currently has limited approved treatment options. The Tezspire eosinophilic esophagitis Phase 3 success is only one part of the wider Amgen story investors may want to...",
                "category": "company",
                "datetime": 1791987290,
                "headline": "What Could Amgen (AMGN) 70% Remission Trial Result Mean For Its Pipeline?"
              },
              {
                "id": 142827405,
                "url": "https://finnhub.io/api/news?id=c51779d3d7df77a8032713ac011bce19574478f7f4bfa06d8b2b04781d1ee56c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Biogen Inc. (NASDAQ:BIIB) closed at $225.71 on October 9. The stock has returned 30.5% during the last six months, compared to a 24.3% return for the Insider Monkey Billionaire Index and 15.1% for the State Street SPDR S&P 500 ETF Trust. Amgen Inc. (NASDAQ:AMGN) closed at $414.87 and has returned 18.6% over the same six […]",
                "category": "company",
                "datetime": 1791851470,
                "headline": "Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?"
              },
              {
                "id": 142767170,
                "url": "https://finnhub.io/api/news?id=64c4c353d4dca7f19b43aa1f78f7fd13c5876b99064e30741b21ea8fb1d6964d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen has climbed to a recent close of US$407.44 after a strong multi year run, which puts fresh focus on whether that price is properly anchored in the cash the business can generate over time. With the stock now carrying solid trailing returns, the key issue for you is how much of Amgen's future cash flow story is already embedded in that quote. Over the past 5 years the share price has delivered a total return of 130.2%, so a lot now depends on whether the underlying cash flows can...",
                "category": "company",
                "datetime": 1791580660,
                "headline": "Amgen (AMGN) Stock Could Be 40% Undervalued On KRAS Market Growth News"
              },
              {
                "id": 142767943,
                "url": "https://finnhub.io/api/news?id=a14612d40f72e892a86222f2ee1f4dffa607a081f8f31f80c5d54a467da5f2cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "In the closing of the recent trading day, Amgen (AMGN) stood at $414.87, denoting a +1.82% move from the preceding trading day.",
                "category": "company",
                "datetime": 1791579004,
                "headline": "Amgen (AMGN) Laps the Stock Market: Here's Why"
              }
            ],
            "raw_source": [
              {
                "id": 143032059,
                "url": "https://finnhub.io/api/news?id=526ca852bd13c84f9eed80033a10f76befd97e38898aa8777ca0e9ae4787d595",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "These drugmakers are facing some near-term challenges, but is that enough to stop their recent momentum?",
                "category": "company",
                "datetime": 1792530000,
                "headline": "2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)"
              },
              {
                "id": 143032084,
                "url": "https://finnhub.io/api/news?id=6efcf496b49209d6d230e15917e232276b948288ff21a77503c61ee118c38eb5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Stock Market Today: The Dow Jones index and other indexes gain Tuesday on U.S.-Iran peace hopes. Biotech and software stocks show strength. A Warren Buffett stock clears an entry.",
                "category": "company",
                "datetime": 1792529297,
                "headline": "Stock Market Today: Dow Jumps On U.S.-Iran Hopes; This Warren Buffett Stock Offers Entry (Live Coverage)"
              },
              {
                "id": 143032200,
                "url": "https://finnhub.io/api/news?id=5c848d001674886769b2d917a07db58cd5a32d4fec810cbfa8a80bdf5a849902",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society of Medical Oncology Congress (ESMO) 2026 on Saturday, October 24, 2026 at 11:30 a.m. PT. Murdo Gordon, executive vice president of Global Markets and Policy at Amgen, and Jean-Charles Soria, senior vice president of oncology within Global Development at Amgen, as well as other members of Amgen's management team, will discuss Amgen's oncology portfolio and selected data being present",
                "category": "company",
                "datetime": 1792527300,
                "headline": "AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026"
              },
              {
                "id": 143032201,
                "url": "https://finnhub.io/api/news?id=72d9c7d26eed0a1a488670e3352435778636df7b1c0dc8159adba45f3ab12657",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "WILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today announced the appointment of Scott M. Wasserman, MD, to the Company’s Board of Directors, effective October 19, 2026. Concurrent with Dr. Wasserman’s appointment, the Company also announced the resignation of Dennis Berma",
                "category": "company",
                "datetime": 1792526460,
                "headline": "Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors"
              },
              {
                "id": 143031349,
                "url": "https://finnhub.io/api/news?id=61323e53dcc376ee8afad37c6ac1326db41dbc4901bd67f1ae117ca1b38c2a10",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Healthcare stocks rose late Tuesday afternoon with the NYSE Healthcare Index gaining 2.2% and the St",
                "category": "company",
                "datetime": 1792526011,
                "headline": "Sector Update: Healthcare Stocks Gain Late Afternoon"
              },
              {
                "id": 143031688,
                "url": "https://finnhub.io/api/news?id=e847f5497219a6ee5fb3303bc66bd6264ef463d03cfa7aef6fad9b678cc7ee61",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Dow Jones top gainers in today's session included 3M, Merck, UnitedHealth, Amgen, Nike, Travelers and Home Depot, with 3M leading the advance at 5.08%.",
                "category": "company",
                "datetime": 1792523451,
                "headline": "Dow Jones Top Gainers in Today's Session: 3M Leads"
              },
              {
                "id": 143031681,
                "url": "https://finnhub.io/api/news?id=881cc041f08f15467b0662fcf5a528cc5c286d59149055686324bb6611907161",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Dow Jones top gainers for the Oct. 20, 2026 US session included MMM, UNH, MRK, JNJ, and AMGN, with the article noting their gains and longer-term performance.",
                "category": "company",
                "datetime": 1792514455,
                "headline": "Dow Jones Top Gainers on Oct. 20, 2026: MMM, UNH, MRK Lead Session"
              },
              {
                "id": 143022281,
                "url": "https://finnhub.io/api/news?id=50f9b627fa3ce0b22af7021f9aebc3e7da826c78555020e22b24b208e054663b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Two drugs, Mounjaro and Zepbound, accounted for $14.9 billion of Eli Lilly's (LLY) $23.0 billion in revenue during fiscal Q2 2026. This leaves Eli Lilly relying on two medicines for most of its sales at a time when the price it gets for them is falling. So why is so much of Eli Lilly's business running through two drugs.",
                "category": "company",
                "datetime": 1792494177,
                "headline": "Is Eli Lilly Stock Too Dependent On Two Drugs?"
              },
              {
                "id": 143025096,
                "url": "https://finnhub.io/api/news?id=1b373b26b7c645dac7d70f0a709c51dc16a4f100bcb29b4522dfc1bdcb756b2b",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": " Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the positive Phase 3 CROSSING trial that showed TEZSPIRE® (tezepelumab-ekko) demonstrated statistically significant and clinically meaningful",
                "category": "company",
                "datetime": 1792487218,
                "headline": "Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points"
              },
              {
                "id": 143025097,
                "url": "https://finnhub.io/api/news?id=2e4fbf300506078558ee2139567b2c14c5036275701bbff449877fa9d16e8a93",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "First and only biologic therapy to achieve statistically significant and clinically meaningful histologic remission and symptom improvements at week 24 that were sustained through week 52 vs. placeboTEZSPIRE attained",
                "category": "company",
                "datetime": 1792487181,
                "headline": "AstraZeneca And Amgen's TEZSPIRE Met Co-Primary Endpoints In Phase III EoE Trial"
              },
              {
                "id": 143019749,
                "url": "https://finnhub.io/api/news?id=cb947ecd6967b5a54aa4c18124cbd7db2a5a26f210b6c82b701f553e4162b4b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen recently reported a 10% rise in second quarter revenue, continued to beat earnings and sales estimates, and maintained a dividend yield of 2.5% with annual increases of 8% from 2020 to 2025. The combination of consistent estimate beats, modest upward earnings revisions and faster dividend growth than Merck signals a business leaning on disciplined capital returns as well as expanding newer therapies. We will look at how Amgen's investment narrative is influenced by sustained dividend...",
                "category": "company",
                "datetime": 1792466582,
                "headline": "How Earnings Beat At Amgen Stock Has Changed Its Investment Story"
              },
              {
                "id": 143020608,
                "url": "https://finnhub.io/api/news?id=5cc767b9143d7093cf8d07efb52939d79cc2dd4f555b5fa8a896fb2d81c14981",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2193136073/image_2193136073.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "RIG portfolio review ranks 15 undervalued vs. 15 overvalued dividend stocks using 52-week highs/lows. Check out the list here.",
                "category": "company",
                "datetime": 1792458299,
                "headline": "15 Undervalued Stocks: Yield Up To 7.8% And 15 Overvalued Not To Pursue Now"
              },
              {
                "id": 143011367,
                "url": "https://finnhub.io/api/news?id=4bd7e95c165bf95aa43ab7d3622bf3ffc1ccf63428c844ba16d8c60e325830fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Key TakeawaysMerck raised its 2026 sales outlook on Aug. 4, the same day Amgen reported second-quarter revenue up 10%.",
                "category": "company",
                "datetime": 1792445995,
                "headline": "Merck vs. Amgen: Which Dividend Stock Pays You More in 10 Years?"
              },
              {
                "id": 143011260,
                "url": "https://finnhub.io/api/news?id=c88344c89e5ede3a8a47ebcd44e909b160fca4cb73c840f8b3251ecf5bf6ab25",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The Dow Jones index slips even as tech stocks climb on stock market today. Amazon and Nvidia rebound while a biotech stock tests a buy point.",
                "category": "company",
                "datetime": 1792442427,
                "headline": "Stock Market Today: Dow Dips As Oil Jumps, Nasdaq Pops; Amazon Stock Rallies On This"
              },
              {
                "id": 143009574,
                "url": "https://finnhub.io/api/news?id=8070bf91d38ecf0cb55fe6c532381fe54aad64d0db7dcf4b2a2b80d46cc14f93",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Regeneron Pharmaceuticals (REGN) stock returned 37.9% in the year to October 16, 2026. This easily outpaced the 16.2% gain for the S&P 500 and left investors looking at a higher price. The underlying business has grown faster lately, yet its operating margin has slipped in each of the past three years. If you buy or hold the shares today, what could three more years of owning them make you.",
                "category": "company",
                "datetime": 1792430174,
                "headline": "How Much Upside Is Left In Regeneron Stock?"
              },
              {
                "id": 143009617,
                "url": "https://finnhub.io/api/news?id=7fc48ad33ab0c584178d44921a5e318db37d75d19ff0e0c85aebc698becc355e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Peter Griffith joins from a biotech company. Paul Ruh, who has been CFO since the spring of 2025, will serve as an adviser through the end of the year.",
                "category": "company",
                "datetime": 1792426560,
                "headline": "Mattel names second CFO in under 18 months"
              },
              {
                "id": 143008585,
                "url": "https://finnhub.io/api/news?id=f52b5fb1beed78b0a5567a9b57fa2e210f10cb83dbe2fa6cd9f4f4a5608b3659",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen Inc. (NASDAQ:AMGN) has carved out a strong spot in the biotech world, thanks to its lineup of medicines for cancer, heart disease, inflammation, and some rare conditions. The company’s tried-and-true products bring in plenty of cash, and its newer treatments show real promise for growth. For those looking beyond a single pharmaceutical stock, the 10 […]",
                "category": "company",
                "datetime": 1792418836,
                "headline": "Amgen Has the Drugs and the Dividend. Now It Needs the Growth"
              },
              {
                "id": 143006755,
                "url": "https://finnhub.io/api/news?id=795ea8d2ea00aecba4daf0b89a83a34013816f2d050c01814823b10699d27ea5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
                "category": "company",
                "datetime": 1792411203,
                "headline": "Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 142992053,
                "url": "https://finnhub.io/api/news?id=338e046f3cae53ba7d15e9918dd078db2c4d26bc477673975dbc84454a9e73f7",
                "image": "",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "",
                "category": "company",
                "datetime": 1792366040,
                "headline": "The Winners Inside SCHD - October 2026"
              },
              {
                "id": 142960043,
                "url": "https://finnhub.io/api/news?id=aaac2ce878fbbecbdb3c56b87a08086dc2008dd01fe01680be3a23d94f641b66",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen is scheduled to report its third-quarter results next month, and analysts expect a single-digit earnings rise.",
                "category": "company",
                "datetime": 1792212374,
                "headline": "Amgen's Q3 2026 Earnings: What to Expect"
              },
              {
                "id": 142957851,
                "url": "https://finnhub.io/api/news?id=7fbbc87921f5eb6aebe1a84de39e7ad8c2e918ec67c718d7d159b99c51415cdb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "An investor who put $10,000 into Eli Lilly (LLY) stock on October 14, 2025 held about $15,500 by October 15, 2026. Placing that same sum in the S&P 500 over the identical period would have yielded about $11,790. By mid-2026, two drugs, Zepbound and Mounjaro, accounted for most of the company's sales. How early did those two drugs show up in what Lilly said and filed.",
                "category": "company",
                "datetime": 1792205822,
                "headline": "What Was Eli Lilly Telling You Before Its Stock Ran?"
              },
              {
                "id": 142955409,
                "url": "https://finnhub.io/api/news?id=ddb56e3c9661675f49062aebfa86d5d29be9a5e9841df1481875ad51a4717ce5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) raised its revenue forecast for fiscal 2026 on August 4. Since the market close before that release, the stock has gained 15.2%, outpacing the 1.9% return of the S&P 500. A higher forecast or a climbing share price means little in isolation. When the corporate numbers and the technical chart align, however, the combination warrants closer scrutiny. So how far did management raise its forecast, and why.",
                "category": "company",
                "datetime": 1792198389,
                "headline": "When Amgen's Forecast And Chart Say The Same Thing, Pay Attention"
              },
              {
                "id": 142953213,
                "url": "https://finnhub.io/api/news?id=e0d5644bdb1a894b876cd8a527913e2c730f1125e7d0685ae819033f70376096",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Investors holding shares of Amgen (AMGN), the $234 billion maker of drugs such as Repatha and Prolia, likely pair that position with broad exposure to the S&P 500. As the broader market rises and falls each day, the pharmaceutical stock's individual performance blends with the rest of that capital. So when the market drops, does Amgen make your losses bigger.",
                "category": "company",
                "datetime": 1792196033,
                "headline": "Is Amgen Stock Increasing Your Market Risk?"
              },
              {
                "id": 142951534,
                "url": "https://finnhub.io/api/news?id=a6ec6823402e68ad6ddd5bb35f18a9ec64b21a46ee6a9622a167015e67770089",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.",
                "category": "company",
                "datetime": 1792183740,
                "headline": "Moderna Stock Slumps, but It’s Too Early to Panic"
              },
              {
                "id": 142950007,
                "url": "https://finnhub.io/api/news?id=af9cc9e28f3a10ea2145e9aa2ce346b5f10ea949ca6edd0654727a5baaf6a007",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "A week that tested the financial markets showed the resilience of Dow Jones stocks. Apple and Coca-Cola were among nine standouts.",
                "category": "company",
                "datetime": 1792179794,
                "headline": "9 Dow Jones Stocks Make Bullish Moves In A Defensive Market Rotation"
              },
              {
                "id": 142950824,
                "url": "https://finnhub.io/api/news?id=74963cb0e70ab8059f861c09846021096b759eb7a9602add0dbe79b1eea9591b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.",
                "category": "company",
                "datetime": 1792179360,
                "headline": "Moderna and Novavax Stocks Slump as Biotech’s Rally Takes a Breather"
              },
              {
                "id": 142961245,
                "url": "https://finnhub.io/api/news?id=4e3a5bc5c0a78c73d698f6130bc0bb938c93a492703cbb6590ee62454ca1ab13",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.45% on an annualized basis producing an average annual return of 14.3%. Currently, Amgen has a market capitalization of $230.37 billion.",
                "category": "company",
                "datetime": 1792150243,
                "headline": "Here's How Much $100 Invested In Amgen 15 Years Ago Would Be Worth Today"
              },
              {
                "id": 142944885,
                "url": "https://finnhub.io/api/news?id=f91f403f3ffc3a12e9d0386f0f23990216287021ab63ad0404ebea0e9b7ed963",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192991654/image_2192991654.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Biogen's Q3 earnings are due Oct 28. Explore FY2026 EPS guidance, Alzheimer’s revenue growth, and key risk/reward drivers—read now. Click for this BIIB update.",
                "category": "company",
                "datetime": 1792139325,
                "headline": "Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)"
              },
              {
                "id": 142923009,
                "url": "https://finnhub.io/api/news?id=00c6c29cc16d7b03ff19880b96b7b8fa827700084fa24fe072030ad3a300a5ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The latest trading day saw Amgen (AMGN) settling at $434.03, representing a +1.86% change from its previous close.",
                "category": "company",
                "datetime": 1792097402,
                "headline": "Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider"
              },
              {
                "id": 142921152,
                "url": "https://finnhub.io/api/news?id=545db4733871e90a22820d700146d007479454afeb887e72faa3fb5e27048e68",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1792091412,
                "headline": "Discover which dow jones stocks are making waves on Thursday."
              },
              {
                "id": 142920416,
                "url": "https://finnhub.io/api/news?id=e1edfeb2d3d1b855f41641b69760edc6c7630a45db8b820a950c2052acbfe992",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen and Merck both yield around 2.3% and have surged this year, but one of them is paying its dividend out of thin air while the other has a cash cushion that changes the entire income calculus.",
                "category": "company",
                "datetime": 1792082725,
                "headline": "AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow"
              },
              {
                "id": 142919827,
                "url": "https://finnhub.io/api/news?id=18dc9eae377f70c9060ce92d31795980c6c5b9529453a1aa557a7ac15259d50c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay updated with the movements of the dow jones index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1792082413,
                "headline": "These dow jones stocks are moving in today's session"
              },
              {
                "id": 142889244,
                "url": "https://finnhub.io/api/news?id=434733031d20fe4cdc19bc79cf48d12b65f1d04ad018b78d4055f1173b8c98bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Regeneron Pharmaceuticals (REGN) may get its next boost from an old deal rather than a new drug. Through the first half of 2026, Regeneron was paying down a balance owed to its partner Sanofi. This obligation reduced the revenue Regeneron reported from the partnership. So what does Regeneron gain now that the balance is paid off.",
                "category": "company",
                "datetime": 1792014348,
                "headline": "What Could Send Regeneron Stock Higher?"
              },
              {
                "id": 142887223,
                "url": "https://finnhub.io/api/news?id=0da62e5b5741f2c815f6c9d71ebb7308149769088a6488e233b3825b4510e5a1",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Wednesday.",
                "category": "company",
                "datetime": 1792005015,
                "headline": "Discover which dow jones stocks are making waves on Wednesday."
              },
              {
                "id": 142885916,
                "url": "https://finnhub.io/api/news?id=b622cb959cbffaf6a3f606c989db14bb104d90fd68454f6db70586c3daa7cf5d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.",
                "category": "company",
                "datetime": 1791995703,
                "headline": "Exploring the top movers within the S&P500 index during today's session."
              },
              {
                "id": 142885266,
                "url": "https://finnhub.io/api/news?id=6ade8008a6f739f7549d16f6ca34b85649df002f32fe2e84eadb492e54b9552c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Why Amgen Stock Is Back In Focus Amgen (AMGN) moved into the spotlight after its share price climbed sharply alongside growing attention on treatments for age related conditions in the U.S., putting its role in an aging society under closer investor scrutiny. Over the past few months, momentum around Amgen has picked up, with a 30 day share price return of 9.41% and a 90 day move of 15.22% helping lift the stock to US$412.84. The 1 year total shareholder return of 44.39% and 5 year total...",
                "category": "company",
                "datetime": 1791991532,
                "headline": "Amgen (AMGN) Gains Attention On Aging Treatments, Is The Upside Already Priced In?"
              },
              {
                "id": 142885264,
                "url": "https://finnhub.io/api/news?id=ed9c9f739ded06f1de88c23820514a376159b3ea00f6238c78d47911212f309d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NasdaqGS:AMGN) and AstraZeneca reported positive Phase 3 results for Tezspire in eosinophilic esophagitis on 14 October 2026. In the trial, nearly 70% of patients receiving the higher Tezspire dose achieved remission at week 24. The study targeted eosinophilic esophagitis, a chronic inflammatory condition that currently has limited approved treatment options. The Tezspire eosinophilic esophagitis Phase 3 success is only one part of the wider Amgen story investors may want to...",
                "category": "company",
                "datetime": 1791987290,
                "headline": "What Could Amgen (AMGN) 70% Remission Trial Result Mean For Its Pipeline?"
              },
              {
                "id": 142885265,
                "url": "https://finnhub.io/api/news?id=3eb31bac32bc70e5f4b3ef4579a9d9893f7b510e98275dea2b52506cf6365294",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Veeva expands its IQVIA partnership with clinical operations software, boosting its market reach and growth prospects through wider adoption and integrated workflows.",
                "category": "company",
                "datetime": 1791985440,
                "headline": "VEEV Expands IQVIA Partnership With Clinical Operations Software Suite"
              },
              {
                "id": 142885267,
                "url": "https://finnhub.io/api/news?id=eb2e090d8288025cac5d06411c289754d71600c3ecc38f76015b215560e05525",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.",
                "category": "company",
                "datetime": 1791984600,
                "headline": "Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?"
              },
              {
                "id": 142882662,
                "url": "https://finnhub.io/api/news?id=d176bc9314d31815c8a35626825fee4c62b329256c1456a4ff8d495e8ab5941c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Retirees watching CD rates scrape bottom and Treasury coupons lock in for a decade have a third option hiding in plain sight inside the Dow Jones Industrial Average, and it requires owning just six stocks.",
                "category": "company",
                "datetime": 1791983740,
                "headline": "How to Turn $500,000 Into a Lazy $16,500 Yearly Passive Income Stream"
              },
              {
                "id": 142882630,
                "url": "https://finnhub.io/api/news?id=5e4289c0c9b96dfa1e95a00694f6be0915f8672c2b831308bed3a3fce09f0551",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-related conditions.",
                "category": "company",
                "datetime": 1791979740,
                "headline": "Bet on These Healthcare ETFs to Benefit From the Aging US Population"
              },
              {
                "id": 142915760,
                "url": "https://finnhub.io/api/news?id=96ad35f5ef177e04917a658689de84478274bbf6edf6e6f298c9a08636fefbf6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/14/Nasdaq-100-way-down.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "The Nasdaq 100 fell 1% by midday Wednesday after September CPI topped forecasts, pushing Treasury yields and rate-hike bets higher.",
                "category": "company",
                "datetime": 1791977994,
                "headline": "Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today"
              },
              {
                "id": 142881756,
                "url": "https://finnhub.io/api/news?id=a3f2fab0fe8cf0c3c08140592360ce9c537164de8862f41573d4d377aedba88f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Boosted by its exclusive agreement with Regeneron, Kiniksa Pharmaceuticals stands among the top biotech stocks to watch.",
                "category": "company",
                "datetime": 1791977440,
                "headline": "Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight"
              },
              {
                "id": 142881695,
                "url": "https://finnhub.io/api/news?id=7fea1d49ce468ac5cda1986cdec52c42bb30275066096747e2bcadca75f062b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway. The five names on this list have already replaced their fading blockbusters with something bigger, and the math behind their payouts tells the story.",
                "category": "company",
                "datetime": 1791976502,
                "headline": "Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying"
              },
              {
                "id": 142869843,
                "url": "https://finnhub.io/api/news?id=310ef25895cc39730bc02d53261c2e29cfcc1b7eb4f0498474d0e9c56b8614e8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1196086989/image_1196086989.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Visible Alpha consensus expects the Dow Jones Industrial Average to deliver an 18.7% weighted price return in the medium term. Read more here.",
                "category": "company",
                "datetime": 1791948000,
                "headline": "Dow Jones Industrial Average Monitor Update - A Look At 30 U.S. Large-Caps"
              },
              {
                "id": 142856069,
                "url": "https://finnhub.io/api/news?id=19ddbf443d05e538002ed8fb8a4b92ac9ed26efb14a4416a1787066e2d586672",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) competes in a tight peer group of six large drugmakers alongside AbbVie, Johnson & Johnson, Merck, Pfizer, and Bristol-Myers Squibb. The company ranks second within this group for both sales growth and operating margin. Its valuation tells a different story. Leaving out Merck and Pfizer, which each reported a loss in at least one of their last four quarters, Amgen has the third highest P/E of the four companies that can be compared. So how far apart are what Amgen delivers and what",
                "category": "company",
                "datetime": 1791935331,
                "headline": "Is Amgen Stock Worth More Than Its Competitors?"
              },
              {
                "id": 142853444,
                "url": "https://finnhub.io/api/news?id=d3c9a96d4f639435dd81c82294ec2c31c03002bcc1a4f295b7f7efba4bcca128",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Investors are currently valuing Eli Lilly (LLY) stock at a premium, with shares priced at 39.5 times earnings compared with 21.9 for the S&P 500. Justifying that multiple may require sustained growth, yet most of Lilly's sales still come from the company's two dominant blockbusters, Zepbound and Mounjaro. The pharmaceutical maker has a newer drug on sale and expects to launch it in all major markets worldwide in 2027. So what is the new drug, and is it selling.",
                "category": "company",
                "datetime": 1791919463,
                "headline": "What Is Eli Lilly Stock's Biggest Opportunity?"
              },
              {
                "id": 142853114,
                "url": "https://finnhub.io/api/news?id=239f1ec0bd6003c75b83346777ebb77ec584c75f68f4c78fd3f43f5a7e2d2574",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Tuesday.",
                "category": "company",
                "datetime": 1791918616,
                "headline": "Explore the top gainers and losers within the dow jones index in today's session."
              },
              {
                "id": 142853459,
                "url": "https://finnhub.io/api/news?id=f00b1416751b9b599ae572eb41364da8c22e0580d73153052166dba042a60169",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "A decent day for the Dow has completely flipped on its head.",
                "category": "company",
                "datetime": 1791913295,
                "headline": "Here’s What’s Dragging Down the Dow"
              },
              {
                "id": 142851845,
                "url": "https://finnhub.io/api/news?id=40d2c5297662fe6576264f21cdd4db7fc189e73028158a4128a0960d9c568eed",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Curious about the dow jones stocks that are in motion on Tuesday? Join us as we explore the top movers within the dow jones index during today's session.",
                "category": "company",
                "datetime": 1791909615,
                "headline": "Discover which dow jones stocks are making waves on Tuesday."
              },
              {
                "id": 142851173,
                "url": "https://finnhub.io/api/news?id=52bfecf14db533640a6652f9c607209b6c62d00634d3c8f1b4329f11c77aa85b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "JNJ beats Q3 earnings estimates but misses sales expectations as MedTech lags. It raises its 2026 sales and earnings outlook.",
                "category": "company",
                "datetime": 1791899820,
                "headline": "J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down"
              },
              {
                "id": 142849615,
                "url": "https://finnhub.io/api/news?id=d7e202d0d63506fdf97094033c7ab33c4c164af25ca485e6d87c802173c0d2a6",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Guggenheim  analyst Vamil Divan   maintains Amgen (NASDAQ:AMGN) with a Neutral and lowers the price target from $388 to $378.",
                "category": "company",
                "datetime": 1791881934,
                "headline": "Guggenheim Maintains Neutral on Amgen, Lowers Price Target to $378"
              },
              {
                "id": 142827405,
                "url": "https://finnhub.io/api/news?id=c51779d3d7df77a8032713ac011bce19574478f7f4bfa06d8b2b04781d1ee56c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Biogen Inc. (NASDAQ:BIIB) closed at $225.71 on October 9. The stock has returned 30.5% during the last six months, compared to a 24.3% return for the Insider Monkey Billionaire Index and 15.1% for the State Street SPDR S&P 500 ETF Trust. Amgen Inc. (NASDAQ:AMGN) closed at $414.87 and has returned 18.6% over the same six […]",
                "category": "company",
                "datetime": 1791851470,
                "headline": "Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?"
              },
              {
                "id": 142822226,
                "url": "https://finnhub.io/api/news?id=2333ac8c91406bf34315edb5c62ab7e754d81f2a9f8505fec08c8fc60def9b8a",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay updated with the movements of the dow jones index in the middle of the day on Monday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1791823213,
                "headline": "Uncover the latest developments among dow jones stocks in today's session."
              },
              {
                "id": 142849616,
                "url": "https://finnhub.io/api/news?id=eee93f7fe1fbc2ce75810ea05073fa1250e88501553f0fa86ec3ce54177db0f5",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "BMO Capital  analyst Evan David Seigerman   maintains Amgen (NASDAQ:AMGN) with a Market Perform and lowers the price target from $450 to $415.",
                "category": "company",
                "datetime": 1791812250,
                "headline": "BMO Capital Maintains Market Perform on Amgen, Lowers Price Target to $415"
              },
              {
                "id": 142822734,
                "url": "https://finnhub.io/api/news?id=4ee58cafef99d236ad14db8eda9642068fbbd06b5a1ed8694ad2ed1c57121250",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.",
                "category": "company",
                "datetime": 1791806940,
                "headline": "Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data"
              },
              {
                "id": 142849617,
                "url": "https://finnhub.io/api/news?id=911b8616049bffee61deb6d7d5dccfc939f29862e88e372985a5fb67c791f73a",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Wells Fargo  analyst Mohit Bansal   maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and lowers the price target from $435 to $430.",
                "category": "company",
                "datetime": 1791804821,
                "headline": "Wells Fargo Maintains Equal-Weight on Amgen, Lowers Price Target to $430"
              },
              {
                "id": 142797825,
                "url": "https://finnhub.io/api/news?id=d0e4c844dfa87ed4f53dd4d26660626a03de6fc78fae246c12d12553264f870b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.",
                "category": "company",
                "datetime": 1791686100,
                "headline": "How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?"
              },
              {
                "id": 142795808,
                "url": "https://finnhub.io/api/news?id=fa88cdfd74ccb3980dd29d4c2cc501cf78fdf54e2897ef5e1a8793016dcd4e94",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "During the October 7 episode of Mad Money, Jim Cramer discussed Veeva Systems Inc. (NYSE:VEEV) as an example of a software business that had recovered from fears about AI disruption, as he said: Take Veeva Systems, the best of its business, makes software for the pharma and biotech industries. Their platform helps capture the whole […]",
                "category": "company",
                "datetime": 1791669349,
                "headline": "Veeva Systems’ (VEEV) Comeback Gets Jim Cramer Talking"
              },
              {
                "id": 142767170,
                "url": "https://finnhub.io/api/news?id=64c4c353d4dca7f19b43aa1f78f7fd13c5876b99064e30741b21ea8fb1d6964d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen has climbed to a recent close of US$407.44 after a strong multi year run, which puts fresh focus on whether that price is properly anchored in the cash the business can generate over time. With the stock now carrying solid trailing returns, the key issue for you is how much of Amgen's future cash flow story is already embedded in that quote. Over the past 5 years the share price has delivered a total return of 130.2%, so a lot now depends on whether the underlying cash flows can...",
                "category": "company",
                "datetime": 1791580660,
                "headline": "Amgen (AMGN) Stock Could Be 40% Undervalued On KRAS Market Growth News"
              },
              {
                "id": 142767943,
                "url": "https://finnhub.io/api/news?id=a14612d40f72e892a86222f2ee1f4dffa607a081f8f31f80c5d54a467da5f2cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "In the closing of the recent trading day, Amgen (AMGN) stood at $414.87, denoting a +1.82% move from the preceding trading day.",
                "category": "company",
                "datetime": 1791579004,
                "headline": "Amgen (AMGN) Laps the Stock Market: Here's Why"
              },
              {
                "id": 142765954,
                "url": "https://finnhub.io/api/news?id=e8e3b8da2da0d6ae4d9558e72857a3ca0885d2701f5b383c0d396564a0c319c7",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Friday.",
                "category": "company",
                "datetime": 1791573008,
                "headline": "Friday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 142765260,
                "url": "https://finnhub.io/api/news?id=78d7d56937e35fb72a555ebcdde33f1c83b79495175690cec5b685b66b4b1abd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Every dividend dollar sitting in a taxable account quietly hands a portion of itself to the IRS year after year, and after two decades that quiet cost compounds into a number most investors never bother to calculate until it is too late.",
                "category": "company",
                "datetime": 1791566103,
                "headline": "The Tax Math That Makes These High-Yield Dividend Stocks Worth Much More Annually Inside a Roth"
              },
              {
                "id": 142765319,
                "url": "https://finnhub.io/api/news?id=450bd746f6107068467344271d2c19332b14377bb6d85805eb7b1026032d6153",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "If envudeucitinib gains approval, it will join an increasingly competitive market flanked by drugs like J&J’s Icotyde, Amgen’s Otezla and BMS’ Sotyktu.",
                "category": "company",
                "datetime": 1791565899,
                "headline": "Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact"
              },
              {
                "id": 142764645,
                "url": "https://finnhub.io/api/news?id=017ffc0a54b8f782db50580fa23a16d185b394840ad8991564195fa4ddb45199",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1791564011,
                "headline": "Top dow jones movers in Friday's session"
              },
              {
                "id": 142763972,
                "url": "https://finnhub.io/api/news?id=6fdf316f2d5ebe8c061465fe438ca485dfe8aabf63f03dc5c9d92f0f44f43b9e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "These companies might bend during a downturn, but they won’t break.",
                "category": "company",
                "datetime": 1791557402,
                "headline": "A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens"
              },
              {
                "id": 142764049,
                "url": "https://finnhub.io/api/news?id=33ef5177fa0c98f377877068c3a5507f0878cfe0d58604eec85f72d8c6c160e5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "JNJ heads into Q3 earnings with strong drug sales and new launches, but Stelara biosimilar competition and MedTech challenges could weigh on growth.",
                "category": "company",
                "datetime": 1791553920,
                "headline": "J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?"
              },
              {
                "id": 142791290,
                "url": "https://finnhub.io/api/news?id=e37451e7b985e0bda0de9215eea6d5f9963eff684b972d13c2f428b5c6b68d18",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "UBS  analyst Michael Yee   maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $430 to $470.",
                "category": "company",
                "datetime": 1791545366,
                "headline": "UBS Maintains Buy on Amgen, Raises Price Target to $470"
              },
              {
                "id": 142736104,
                "url": "https://finnhub.io/api/news?id=bff74f60d6f2160c55eb02e7e452a8c1637af7ee73d80472a98ad1b017bcc0e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Regeneron Pharmaceuticals (REGN) stock currently trades at 17.6 times earnings. That represents a notable discount to the 21.5 multiple of the median S&P 500 company. The shares have lost 4.1% over the past six months, trailing the 15.7% return of the broader index. Over twelve months, however, the stock returned 27% against the index's 17.1%. A valuation this low suggests investors are either overlooking a sound drug maker or pricing in underlying problems. So how healthy is the business you wo",
                "category": "company",
                "datetime": 1791505165,
                "headline": "What Is Going On With Regeneron Stock?"
              },
              {
                "id": 142731799,
                "url": "https://finnhub.io/api/news?id=d02e79ecef043a92ebba46248d20db4281c6aa7162d4da8ddbe12ca8c3b04577",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Thursday.",
                "category": "company",
                "datetime": 1791486615,
                "headline": "Exploring the top movers within the dow jones index during today's session."
              },
              {
                "id": 142727406,
                "url": "https://finnhub.io/api/news?id=dc6533dc2e9ff30caaea56877baf2b8fd69c924ce2059dce573a54e72a4be388",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Argenx unexpectedly scrapped a study of its drug, Vyvgart, in patients with Sjogren's disease on Thursday. The stock plummeted in response.",
                "category": "company",
                "datetime": 1791466846,
                "headline": "Former Highflier Argenx Plummets On A Surprise Setback In Sjogren's"
              },
              {
                "id": 142727204,
                "url": "https://finnhub.io/api/news?id=0777919541fde067a3ae7f2057a4e37174b1a46ec3889aa06a812dc2cfa4d84e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) stock has returned 44% over the past twelve months, easily outpacing the 17.1% gain for the S&P 500. Investors looking at that rally might question what catalysts remain to push shares higher. One candidate is an experimental therapy that is not yet on the market, and executives say its development is progressing rapidly. So what is that drug, and how far along is it.",
                "category": "company",
                "datetime": 1791464604,
                "headline": "What Would It Take For Amgen Stock To Move Higher?"
              },
              {
                "id": 142729632,
                "url": "https://finnhub.io/api/news?id=7fd2775bdfbca37e1bcb7a875da36b61cbf25fb0684478ca172d2b856d8d15cf",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1495638667/image_1495638667.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Adlai Nortye Group has surged ~1,600% since Dec. 2025, fueled by private placements and preclinical data for its pan-RAS[ON] inhibitor AN9025. Learn more about ANL stock here.",
                "category": "company",
                "datetime": 1791459923,
                "headline": "Adlai Nortye Group: Only For The Risk-Tolerant After A Massive Rally"
              },
              {
                "id": 142762591,
                "url": "https://finnhub.io/api/news?id=3c32f26cd502fa50d61b778fbfec3ed11e3cbf75096fc4be6d7f5999f6ce80c5",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "RBC Capital  analyst Luca Issi   maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $400 to $430.",
                "category": "company",
                "datetime": 1791455977,
                "headline": "RBC Capital Maintains Outperform on Amgen, Raises Price Target to $430"
              },
              {
                "id": 142726804,
                "url": "https://finnhub.io/api/news?id=8712679e68035a7653e67a091e12385ff8167b48802366bb003849d81147b513",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Analysts raised targets for Everpure, Eli Lilly and Delek US, while cutting targets for Constellation, Tyler, ArriVent and Netflix.",
                "category": "company",
                "datetime": 1791449882,
                "headline": "Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday"
              },
              {
                "id": 142727923,
                "url": "https://finnhub.io/api/news?id=90275bcecee4159c6e02a7d1de1abdbfeab978640da0ed16e342a9b6656b94a4",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $400 to $440.",
                "category": "company",
                "datetime": 1791441668,
                "headline": "Cantor Fitzgerald Maintains Neutral on Amgen, Raises Price Target to $440"
              },
              {
                "id": 142708233,
                "url": "https://finnhub.io/api/news?id=2f7346a9610ce7a46550303e106c59f85364191e00a6d9746be48be2ee94a357",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "During the October 1 episode of Mad Money, Jim Cramer discussed Amgen Inc. (NASDAQ:AMGN) while reviewing the Dow Jones Industrial Average’s third-quarter performance. He then shifted his attention to Johnson & Johnson (NYSE:JNJ), as he said: In the end, I think the best lessons from the third quarter came from the 30 stocks in the […]",
                "category": "company",
                "datetime": 1791431126,
                "headline": "Amgen (AMGN) and Johnson & Johnson (JNJ) Catch Jim Cramer’s Eye for Different Reasons"
              },
              {
                "id": 142701310,
                "url": "https://finnhub.io/api/news?id=be0a7e3fa760ed5f0a5c52227739c617a8ce6b41a96fbf2c446e8d620797eaa5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Exelixis (EXEL) stock has returned 46% over the past twelve months, compared with 17.8% for the S&P 500. The company has aggressively repurchased its own stock, reducing its total share count by 21% over the last three years. Because fewer shares remain in circulation, each one lays claim to a larger slice of the profit. So how much is that buyback adding to each Exelixis share you own.",
                "category": "company",
                "datetime": 1791414880,
                "headline": "Is Exelixis Stock Engineered To Make You Money?"
              },
              {
                "id": 142700258,
                "url": "https://finnhub.io/api/news?id=b5b5cee0eabc203182b64c219ab200fa5b1f4d2e3ded9d06b9d6f3715174bcdd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The Dow Jones index drops 500 points Wednesday as Treasury yields jump. The Fed minutes are due later in the day.",
                "category": "company",
                "datetime": 1791407611,
                "headline": "Stock Market Today: S&P 500, Nasdaq Cut Losses; Nuclear Play Holds Firm"
              },
              {
                "id": 142701376,
                "url": "https://finnhub.io/api/news?id=585cf9503c3c18038ad725ac1337defbbd4ade0305511fbd21aabdf794263ad2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "In the closing of the recent trading day, Amgen (AMGN) stood at $413.08, denoting a +2.6% move from the preceding trading day.",
                "category": "company",
                "datetime": 1791406802,
                "headline": "Amgen (AMGN) Advances While Market Declines: Some Information for Investors"
              },
              {
                "id": 142700318,
                "url": "https://finnhub.io/api/news?id=bbc077f2bed73509ccbbbdf77e170ed9eb13fbb99ec147f5b11a941fbe75838b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The healthcare sector stood out as one of the few bright spots in Wednesday’s trading.",
                "category": "company",
                "datetime": 1791404398,
                "headline": "Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets"
              },
              {
                "id": 142699250,
                "url": "https://finnhub.io/api/news?id=69f89736d6b1ba81d734e7398bc3c5f814102bfd2e55fe2ec47378e8ee40e754",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The Dow Jones index drops 500 points Wednesday as Treasury yields jump. The Fed minutes are due later in the day.",
                "category": "company",
                "datetime": 1791401324,
                "headline": "Stock Market Today: S&P 500 Cuts Losses As Oil, Yields Drop But Caterpillar Shares Get Pounded (Live Coverage)"
              },
              {
                "id": 142699052,
                "url": "https://finnhub.io/api/news?id=79cbbb6a9394d74f43ed5875e5d2b638c156a24824ea95997addfce18685ce40",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay updated with the movements of the dow jones index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1791400214,
                "headline": "Top dow jones movers in Wednesday's session"
              },
              {
                "id": 142697832,
                "url": "https://finnhub.io/api/news?id=7035659f7d8a2a0d5730ed16bd3bcb7683148f81f5fe35ce66fb9682da838018",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Wednesday.",
                "category": "company",
                "datetime": 1791391212,
                "headline": "Which dow jones stocks are moving on Wednesday?"
              },
              {
                "id": 142697831,
                "url": "https://finnhub.io/api/news?id=683287b687d95e857a785c1de492dffd35b70d6ff8db3972eb817f9a09d627d2",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay updated with the movements of the S&P500 index in the middle of the day on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1791390901,
                "headline": "Wednesday's session: top gainers and losers in the S&P500 index"
              },
              {
                "id": 142698403,
                "url": "https://finnhub.io/api/news?id=24cab9c3b44d655fea5e81162fe16de373b29b91fba1401c2a64dc187a69aaff",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Eli Lilly (LLY) stock is priced at 38.7 times earnings, compared with 21.5 for the S&P 500. Investors evaluating that valuation should weigh what drives it, especially since the company's priorities have shifted. In late 2024, management opened its earnings call by detailing how many doses of its weight-loss and diabetes drugs it could manufacture. Today, the primary focus has broadened considerably beyond factory output. So what is it.",
                "category": "company",
                "datetime": 1791389636,
                "headline": "Why You Should Think About Eli Lilly Stock Differently Now"
              },
              {
                "id": 142694871,
                "url": "https://finnhub.io/api/news?id=18ecbcab70a7d0bc6608a842a39503d6cdaba5ef96e3465883a1fa2555630bc1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NasdaqGS:AMGN) took part in Arboretum LifeSciences' US$30 million Series A funding round focused on precision medicine. Arboretum LifeSciences plans to apply AI-driven genetic testing and molecular data tools to support more targeted healthcare decisions. The collaboration gives Amgen access to next-generation molecular information that may inform genomically targeted clinical trial design. There is more to Amgen's outlook than its Arboretum LifeSciences Series A funding participation...",
                "category": "company",
                "datetime": 1791378456,
                "headline": "Amgen (AMGN) Backs $30 Million Series A Round In AI Genetic Testing"
              },
              {
                "id": 142696865,
                "url": "https://finnhub.io/api/news?id=f5cc9877b0d6b56d9f45c7b5926b6c81bc5d7a245f22a4efe3e081f0f0ea3d56",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1749214597/image_1749214597.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "October 2026 finds 21 of 30 Dow stocks with sufficient free cash flow to support dividends, but none are ideally fair-priced by yield standards.",
                "category": "company",
                "datetime": 1791372708,
                "headline": "October Dogs Of The Dow: No Buys But 10 Are Worth Watching"
              },
              {
                "id": 142727924,
                "url": "https://finnhub.io/api/news?id=5d12b579442c5e3bef991b532d0101f36a1a1ac01094c0abda09da4deb16c9be",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Truist Securities  analyst Gregory Renza   maintains Amgen (NASDAQ:AMGN) with a Hold and raises the price target from $362 to $380.",
                "category": "company",
                "datetime": 1791371145,
                "headline": "Truist Securities Maintains Hold on Amgen, Raises Price Target to $380"
              },
              {
                "id": 142695952,
                "url": "https://finnhub.io/api/news?id=8d0cda13f8dac61939860d5deb95063fcf1d0e48d404f4569bd40f8ee7ecb0b0",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Morgan Stanley  analyst Terence Flynn   maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and lowers the price target from $362 to $359.",
                "category": "company",
                "datetime": 1791368565,
                "headline": "Morgan Stanley Maintains Equal-Weight on Amgen, Lowers Price Target to $359"
              },
              {
                "id": 142667426,
                "url": "https://finnhub.io/api/news?id=d746261ff29e9cc44ef27036fcaea7bc30f5ad242ea1e6c22ec443fb552f4afd",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Curious about the top performers within the dow jones index one hour before the close of the markets on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1791313811,
                "headline": "Stay informed with the top movers within the dow jones index on Tuesday."
              },
              {
                "id": 142662879,
                "url": "https://finnhub.io/api/news?id=d705ac8bbc1a84771105f38aa40b1a33e4d5758ef9d3290847880283eb6a42f9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.",
                "category": "company",
                "datetime": 1791291394,
                "headline": "2 Nasdaq 100 Stocks Worth Investigating and 1 We Question"
              },
              {
                "id": 142663034,
                "url": "https://finnhub.io/api/news?id=e7dc264606b376301f80bcb2ce874dd044bb26ab44209f88361f2d3d6b53b13a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1791288004,
                "headline": "Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It"
              },
              {
                "id": 142663035,
                "url": "https://finnhub.io/api/news?id=0d8e033e32e58d924869cfeb3451cdfdc3a2e75cc7006065c6c6eb170d96ead5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapiesTEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of biopharmaceutical executive Laura Hamill to its Board of Directors, effective December 1, 2026. Ms. Hamill brings more than 35 years of global commercial, market",
                "category": "company",
                "datetime": 1791288000,
                "headline": "Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise"
              },
              {
                "id": 142662066,
                "url": "https://finnhub.io/api/news?id=c4cb4356883274fb3948c4bc891a538d695bb9aa998033f89f281b11f4c2a55c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "CAMBRIDGE, Mass., October 06, 2026--Arboretum LifeSciences, Inc., a next-generation molecular information company, launched today with a mission to make precision medicine a reality for some of the most common diseases that impact patients around the world. Founded by leaders in data science from the Broad Institute, Arboretum’s approach integrates AI and genetic testing to expand access to genomic medicine for patients and enable recruitment of genomically profiled patients for clinical researc",
                "category": "company",
                "datetime": 1791284400,
                "headline": "Arboretum Launches to Redefine Precision Medicine for Common Diseases as a Next-Generation Molecular Information Company"
              },
              {
                "id": 142638289,
                "url": "https://finnhub.io/api/news?id=0e88a10f0ad90454a5ff9c1b9d8c6be70f11a0beeaf98797fe4fc38372abaa20",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay informed about the performance of the dow jones index one hour before the close of the markets on Monday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1791227409,
                "headline": "Monday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 142662618,
                "url": "https://finnhub.io/api/news?id=d78ffd39021735e4739cfbbd4e7ce2c89bcdbad94ff4f003fc44637d8d221831",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/05/Nasdaq-Inscription-Next-To-Us-Dollars--T.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQQ has beaten equal-weight QQQE by 8% since late July.",
                "category": "company",
                "datetime": 1791212429,
                "headline": "Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average"
              },
              {
                "id": 142636798,
                "url": "https://finnhub.io/api/news?id=02b55fb819eac16ad9dadcdcb5f78fd4425f22a5be3f5f3a3aaf11e2f425c375",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "One thing stands out at Eli Lilly (LLY): how many prescriptions are written for Zepbound and Mounjaro, which may be what buyers are betting on. You may think of them as high-priced drugs, but their U.S. prices are now falling. Yet the stock costs 38.2 times earnings, against 21.5 for the S&P 500. That is the tension. So, how much are the two drugs actually selling.",
                "category": "company",
                "datetime": 1791209955,
                "headline": "Has Eli Lilly Stock Peaked?"
              },
              {
                "id": 142624185,
                "url": "https://finnhub.io/api/news?id=773d3787e684fba498bba3b49094c209329c0e46fcca5973e7c495eb6d0c1b89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.",
                "category": "company",
                "datetime": 1791124497,
                "headline": "Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142591361,
                "url": "https://finnhub.io/api/news?id=95613688eae498627faf1e9092765e34d9fd7c907f05ffb6d9f5ff73e0147392",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Curious about the top performers within the dow jones index in the middle of the day on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1790959214,
                "headline": "What's going on in today's session: dow jones movers"
              },
              {
                "id": 142588430,
                "url": "https://finnhub.io/api/news?id=6d010eb7ec552adf9cf2d8123c73e1a7f1896ededdb70c290de2c2b3673c63d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "JNJ's Innovative Medicine segment is poised for another quarter of growth, with oncology and new launches helping offset Stelara's biosimilar-driven decline.",
                "category": "company",
                "datetime": 1790944200,
                "headline": "J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to Watch"
              },
              {
                "id": 142587475,
                "url": "https://finnhub.io/api/news?id=7540d2683c44b228b44a5985be3027fee4b8b4cfd01d701db6e2852ffcab3a9f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The biggest names in corporate America call the Dow Jones (^DJI) home, but only a handful are still growing at a strong pace. Some of these blue-chip stocks are standing out by adapting to change and driving shareholder value.",
                "category": "company",
                "datetime": 1790941803,
                "headline": "3 Dow Jones Stocks with Exciting Potential"
              },
              {
                "id": 142590413,
                "url": "https://finnhub.io/api/news?id=01a506892fb08f8eff357f6859afe071aae5721e19afeb13ae73cd3d5d348f4b",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "October 1, 2026 records indicate that Representative David Taylor filed a purchase of Amgen (NASDAQ:AMGN), valued between $3,003 and $45,000. According to the October filing, the transaction occurred on September 22,",
                "category": "company",
                "datetime": 1790938824,
                "headline": "Ohio Rep. David Taylor Bought Up to $45K Worth of Amgen Stock"
              },
              {
                "id": 142579657,
                "url": "https://finnhub.io/api/news?id=3d01e5fd3ce0a45e8a98cbb33ce9ed23e42e11c59ab96af4b45c37e6b106e207",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2277133401/image_2277133401.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "The GLP-1 market continues to expand rapidly yet remains in the early stages of growth. The GLP-1 market is no longer simply a weight-loss story.",
                "category": "company",
                "datetime": 1790914860,
                "headline": "GLP-1s: Still Early In The Growth Story"
              },
              {
                "id": 142562935,
                "url": "https://finnhub.io/api/news?id=d5cc5674cab6b90363743d3b55d6f7d816903b3b4640bae8b55ec381c74ae193",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) closed at $407.27 in the latest trading session, marking a -3.38% move from the prior day.",
                "category": "company",
                "datetime": 1790887802,
                "headline": "Amgen (AMGN) Stock Dips While Market Gains: Key Facts"
              },
              {
                "id": 142560840,
                "url": "https://finnhub.io/api/news?id=e1c08e4bbb8e459a2d7b192134c7bdddeb78f099fdf34d930fe361886eba3ba7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Eli Lilly (LLY) management said on its second-quarter 2026 call that the price of Zepbound, its obesity drug, will go down. The company's sales growth rests on two drugs whose prices are falling - Zepbound and Mounjaro. That makes it difficult to call the stock's coming twelve months. So how do you really understand the risk you are taking with Eli Lilly stock? Well, you can look at the options market.",
                "category": "company",
                "datetime": 1790869272,
                "headline": "What Is The Options Market Telling Us About Eli Lilly Stock?"
              },
              {
                "id": 142557733,
                "url": "https://finnhub.io/api/news?id=884d4eb42507bdd7297f3abee12f004467d90d4f489091c768d42a4d510f4394",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.",
                "category": "company",
                "datetime": 1790858880,
                "headline": "Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win"
              },
              {
                "id": 142549220,
                "url": "https://finnhub.io/api/news?id=d6d0e63a7a1be3923e3d71d8d7bb2ef9d72ce93675d91df0ea2d89f8728c4fea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.",
                "category": "company",
                "datetime": 1790843347,
                "headline": "2 Profitable Stocks with Exciting Potential and 1 We Find Risky"
              },
              {
                "id": 142517266,
                "url": "https://finnhub.io/api/news?id=8d2449e550c610a33bf877d009c9dcc982c2ef4a8798578f4761789398bd1cdf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Demand for biologics, targeted therapies and personalized medicine is rising, while AI-led protein design and scalable bioprocessing unlock new opportunities.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- \"Recombinant Proteins Market - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. The global recombinant proteins market was valued at US$3.3 billion in 2024 and is projected to reach US$5.8 billion by 2030, expanding at a compound annual growth rate of 10.2%. Ma",
                "category": "company",
                "datetime": 1790775000,
                "headline": "Recombinant Proteins Market - Global Strategic Business Report: Sales Hit to $5.8 Billion by 2030 - Benchmark Thermo Fisher Scientific, Merck KGaA, Amgen, Bio-Techne and GenScript Biotech Amid Tariff Disruption"
              },
              {
                "id": 142499987,
                "url": "https://finnhub.io/api/news?id=d86a89f12f7a3769625ba57f71398b516023a72b2444d33a1d6a23ea31e36d7c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1790709009,
                "headline": "Which dow jones stocks are moving on Tuesday?"
              },
              {
                "id": 142500357,
                "url": "https://finnhub.io/api/news?id=867d24414fff59a62dd175f863f0568d4caf341cfdc7d4be5570a573cb403329",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "You may own Eli Lilly (LLY), a drugmaker worth about $1.05 trillion, beside funds that already track the S&P 500. A single stock can become a big part of your money, so its daily moves matter for all of it. Is Eli Lilly stock a good fit for the risk you already carry.",
                "category": "company",
                "datetime": 1790707394,
                "headline": "Is Eli Lilly Stock a Good Fit For Your Portfolio Risk?"
              },
              {
                "id": 142499376,
                "url": "https://finnhub.io/api/news?id=c06ff2c0c822e8896c0b556b2872150995680256580705e1edafdf2fc7709e30",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Eli Lilly (LLY) raised its revenue forecast for 2026 on August 5, when it reported second-quarter results. Since the close before that release, Eli Lilly stock has gained 6.3%, while the S&P 500 fell 0.7%. The raise was modest and came with a lower earnings forecast, which is why the price chart is worth a look. So does Eli Lilly's price chart agree with management.",
                "category": "company",
                "datetime": 1790699015,
                "headline": "Management Raised the Bar For Eli Lilly Stock; Does The Chart Agree?"
              },
              {
                "id": 142495875,
                "url": "https://finnhub.io/api/news?id=37e5d29ddd2e61fae3bd84771e2f392450f958a99706d0476b2e8f2990769b50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.",
                "category": "company",
                "datetime": 1790686997,
                "headline": "Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead"
              },
              {
                "id": 142495975,
                "url": "https://finnhub.io/api/news?id=f15c724f6105d6d95539f264faaf206a025426fe0467e8ba0d6ed52ecc1cb827",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "LONDON, September 29, 2026--Keyron, developer of the ForePass® fully reversible metabolic bypass platform for severe metabolic disease, today announced that David Feigal, MD, was appointed Board Chair effective September 21, 2026.",
                "category": "company",
                "datetime": 1790683560,
                "headline": "Keyron Appoints Former FDA Medical Device Center Director David Feigal as Board Chair"
              },
              {
                "id": 142497751,
                "url": "https://finnhub.io/api/news?id=5235fde7279602983862783769265b9f8026f0a3eb72b7846486de58b5a3b4d7",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Scotiabank  analyst Louise Chen   maintains Amgen (NASDAQ:AMGN) with a Sector Outperform and raises the price target from $450 to $500.",
                "category": "company",
                "datetime": 1790679452,
                "headline": "Scotiabank Maintains Sector Outperform on Amgen, Raises Price Target to $500"
              },
              {
                "id": 142479811,
                "url": "https://finnhub.io/api/news?id=0714d67165220c8b178a13db884659ebba3b5e3fa2614bf91c2118312f3effd4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2244980373/image_2244980373.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Pfizer has a compelling risk-reward profile despite near-term COVID normalization and patent expiry headwinds. Find out why PFE stock is a Buy.",
                "category": "company",
                "datetime": 1790649185,
                "headline": "Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough"
              },
              {
                "id": 142473991,
                "url": "https://finnhub.io/api/news?id=df178d2cf28b68a6479514c8d786c42bb77575604a879c90735e17d894ffa26e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "On September 22, Amgen Inc. (NASDAQ:AMGN) announced positive topline Phase 3 results for dazodalibep in systemic Sjögren’s disease. The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in systemic disease activity. Following the announcement, Citi reaffirmed a Neutral rating and $405 price target on Amgen. While Citi noted that the results […]",
                "category": "company",
                "datetime": 1790645237,
                "headline": "Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?"
              },
              {
                "id": 142473995,
                "url": "https://finnhub.io/api/news?id=931cc528ffa23fc1a52a717f4fbb7f43817541f0870ba0452e4a1137489da6ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (AMGN) just reported positive topline data from its Phase 3 OASIZ 301 trial of dazodalibep in Sjögren's disease, an update that puts fresh attention on the stock's autoimmune pipeline potential. Set against that clinical update, Amgen’s share price has climbed 15.5% over the past 90 days and 27.6% year to date, while the 1-year total shareholder return of 56.9% and 5-year total shareholder return of 131.0% point to strong longer term momentum building around the story. Spot emerging...",
                "category": "company",
                "datetime": 1790640510,
                "headline": "Amgen (AMGN), What Is Behind The Fresh Attention?"
              },
              {
                "id": 142470271,
                "url": "https://finnhub.io/api/news?id=417450ff02c63ffe315af3a2768ffe4b7160e1bceb7f00aed5677567e43a78e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Roche’s push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body weight in a mid-stage trial. The results add another potentially important asset to Roche’s efforts to challenge obesity-market […]",
                "category": "company",
                "datetime": 1790625509,
                "headline": "Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?"
              },
              {
                "id": 142625209,
                "url": "https://finnhub.io/api/news?id=22a4d3eff8134e2d0ea7115d3020c487a9fea4883b53f3e01e9205f17c6de17f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 121 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. This Week’s Ratings Changes: Up",
                "category": "company",
                "datetime": 1790622819,
                "headline": "Eli Lilly Upgraded, Intel Downgraded: Updated Rankings on Top Blue-Chip Stocks"
              },
              {
                "id": 142469837,
                "url": "https://finnhub.io/api/news?id=e7314e47396ff982ffb99f585545511c858008d4c9e0017fe81912982ec663c9",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Curious about the dow jones stocks that are in motion on Monday? Join us as we explore the top movers within the dow jones index during today's session.",
                "category": "company",
                "datetime": 1790622615,
                "headline": "Top dow jones movers in Monday's session"
              },
              {
                "id": 142465815,
                "url": "https://finnhub.io/api/news?id=ca90682f5ea9c24da7a452467c520d9d0fafb31e823d2d8f774047a507180b07",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Microsoft, Bloom Energy and Amgen highlight Zacks' latest market moves, with strong gains across Focus List, recommendation and dividend portfolios.",
                "category": "company",
                "datetime": 1790597520,
                "headline": "Take the Zacks Approach to Beat the Markets: Bloom Energy, Microsoft & Amgen in Focus"
              },
              {
                "id": 142464030,
                "url": "https://finnhub.io/api/news?id=0afd57ff68847397d948f41739d87bc211a528946350f034001b3d5f2c0e572b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to DelveInsight, the KRAS inhibitors market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, with the United States expected",
                "category": "company",
                "datetime": 1790596800,
                "headline": "KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034"
              },
              {
                "id": 142450079,
                "url": "https://finnhub.io/api/news?id=a43f2950d4aef148f026dfd83514d351369df2b88276bb021d1d1ae3ad8df8a4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen Inc. (NASDAQ:AMGN)’s experimental drug dazodalibep met the main goal of a late-stage trial for Sjögren’s disease. After 48 weeks, patients with moderate-to-severe disease activity showed statistically significant and clinically meaningful improvements. Most adverse events were mild to moderate, and only a small number of patients stopped treatment. Sjögren’s affects about 1% of the global […]",
                "category": "company",
                "datetime": 1790541271,
                "headline": "Why Amgen’s Pipeline Just Got More Interesting"
              },
              {
                "id": 142450080,
                "url": "https://finnhub.io/api/news?id=f75773aca7966f72ecba1f996fe41f9a0a4d253b3fd3c8317f9f94c82f8be7ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen Inc. (NASDAQ:AMGN) has sold its office campus in Deerfield, Illinois, for $151 million. The buyer is an entity tied to Mesirow, a financial services firm based in Chicago. Amgen is not leaving. It has signed a long-term lease to stay on the roughly 660,000-square-foot campus, where it occupies one of the three buildings. The […]",
                "category": "company",
                "datetime": 1790538955,
                "headline": "Amgen (AMGN) Sells its Deerfield Campus for $151 Million and Leases it Back"
              },
              {
                "id": 142424869,
                "url": "https://finnhub.io/api/news?id=2850530e7bfac77eb273b56b0a9208715941d62e8197fa679600f877f4a54e5a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says.",
                "category": "company",
                "datetime": 1790513160,
                "headline": "Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts."
              },
              {
                "id": 142440672,
                "url": "https://finnhub.io/api/news?id=becdafb046515919da85f72434ea657c96efa03ea7b144c94184a78f1d8899cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "And there could be more positive developments ahead.",
                "category": "company",
                "datetime": 1790454061,
                "headline": "2 Healthcare Stocks That Just Delivered Great News for Investors"
              },
              {
                "id": 142426324,
                "url": "https://finnhub.io/api/news?id=d6c5c69ec31421c27b1a6975d210061fa66349501c956d7486fa7d4d688caafa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Mesirow CEO Richard S. Price with 1 Horizon Way in Deerfield (Getty, Mesirow, Google Maps)An entity tied to Chicago financial services firm Mesirow bought the Amgen office complex in Deerfield in a sale-leaseback deal for $151 million. The deal for the property, which spans 660,000 square feet of office space in three buildings at 1 Horizon Way along I-294 in suburban Deerfield, is rare for a site of its 70-acre size, according to Crain’s. The suburbs still suffer from high vacancy rates and sha",
                "category": "company",
                "datetime": 1790373600,
                "headline": "Amgen’s Deerfield office campus sold to Mesirow for $151M in sale-leaseback deal"
              },
              {
                "id": 142426158,
                "url": "https://finnhub.io/api/news?id=e251de3ee1fb6ad2f8cc5fbbac25fe149678f818e3d861de79643847128feaeb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "In the latest trading session, Amgen (AMGN) closed at $414.61, marking a +2.11% move from the previous day.",
                "category": "company",
                "datetime": 1790369402,
                "headline": "Amgen (AMGN) Rises Higher Than Market: Key Facts"
              },
              {
                "id": 142424741,
                "url": "https://finnhub.io/api/news?id=4308d9f07c323d9021d073923c5f70cf5e06f382b2dbc2eeb465bb50bd05e10e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "At about $1,182 a share, Eli Lilly (LLY) stock trades at about 33.1 times trailing earnings. Those are adjusted earnings: normalized net income with stock-based compensation added back, a basis built to sit close to the one analysts use in their forecasts. That looks expensive. Whether it is depends on two obesity drugs, on margins and on how much Lilly spends buying new medicines.",
                "category": "company",
                "datetime": 1790356391,
                "headline": "Is LLY Stock Cheaper Than It Looks?"
              },
              {
                "id": 142425004,
                "url": "https://finnhub.io/api/news?id=ff6983ae53d6ccc1e09f0dc6e30c545fcf2fba94e386e2209c7847467b9be2c7",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/965085606/image_965085606.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Build a $75K dividend portfolio anchored by SCHD, enhanced with JEPI, VNG, and 8 quality stocks to boost yield, growth, and diversification—read now.",
                "category": "company",
                "datetime": 1790344800,
                "headline": "How To Build A $75,000 Dividend Portfolio With SCHD And 5 High-Yield Picks"
              },
              {
                "id": 142423779,
                "url": "https://finnhub.io/api/news?id=81197abef2780c8915d74ff433da1704ae1e26f8c103bc00e865d53ee6479373",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Keystone, a global advisory firm that guides the most critical technology and science-based platforms and ecosystems, today announced it is establishing Keystone India, with Bengaluru as its first hub in the country. The company plans to hire talent and expand its workforce in India over the next two years.",
                "category": "company",
                "datetime": 1790344800,
                "headline": "Keystone To Launch India Business With Bengaluru As First Hub, Plans To Hire Talent & Increase Workforce Over Next Two Years"
              },
              {
                "id": 142437380,
                "url": "https://finnhub.io/api/news?id=50d878b82a064951cdb9c0d340c1b407a22468c7e52c48167fc1ae5b0f4eb515",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1790343311,
                "headline": "10 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 142422639,
                "url": "https://finnhub.io/api/news?id=f2d431c14c60c08578ba84b3b1457a48d7838580e7c3b3850780e9babfdb9f32",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Rising Treasury yields are reshaping market preferences, putting dividend growth stocks like EnerSys and Amgen in focus for income and growth.",
                "category": "company",
                "datetime": 1790339280,
                "headline": "Bet on These 5 Dividend Growth Stocks Amid Rising Treasury Yields"
              },
              {
                "id": 142424832,
                "url": "https://finnhub.io/api/news?id=ef4cccb9c97a23c459807400baaf9529ba05189df9a67642944118ca63c3d5a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.",
                "category": "company",
                "datetime": 1790337604,
                "headline": "Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know"
              },
              {
                "id": 142400304,
                "url": "https://finnhub.io/api/news?id=20b8ae04a3299406d93c630dcf0170a4c5ec9d18d2627dcb94a457ccded4bd0d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "In recent days, Veeva Systems has rolled out new AI-powered tools such as Veeva Study Builder Agent and Veeva Falcon Router, while announcing major customer wins including Oxford Biomedica adopting Veeva Quality Cloud and Amgen planning a global deployment of Veeva Vault CRM. Together, these developments highlight Veeva’s push to embed agentic AI across clinical, safety, quality, and commercial workflows, reinforcing its role as an end-to-end software partner for life sciences...",
                "category": "company",
                "datetime": 1790316625,
                "headline": "How Investors Are Reacting To Veeva Systems (VEEV) Expanding Agentic AI And Winning New Pharma Clients"
              },
              {
                "id": 142386787,
                "url": "https://finnhub.io/api/news?id=3ffaa0dfb444fd4900742feb9b4ba2aa7ff38b75aeba7b6b61fa3cb9ce6f3011",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at therapeutics stocks, starting with Amgen (NASDAQ:AMGN).",
                "category": "company",
                "datetime": 1790284378,
                "headline": "Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks"
              },
              {
                "id": 142385318,
                "url": "https://finnhub.io/api/news?id=39315ae599bd174ef47d4654149a800f3939b9271d7fc496d8612dfacb99059d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Curious about the top performers within the dow jones index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1790277010,
                "headline": "Stay informed with the top movers within the dow jones index on Thursday."
              },
              {
                "id": 142385630,
                "url": "https://finnhub.io/api/news?id=310a05043333dd66b6c91061efb6b5de359e48bd49da83dcd28571596ab9731c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Eli Lilly (LLY) grew revenue 49.6% over the last twelve months, the fastest of the six companies in its peer group. It also runs the group's widest operating margin, at 49.7%. Yet its 53.4% stock return ranks only third, behind Merck and Johnson & Johnson, which both grew far more slowly. The open question is how long Mounjaro and Zepbound can carry a lead the stock has not matched.",
                "category": "company",
                "datetime": 1790276631,
                "headline": "Can Eli Lilly Stock Catch Up To Rivals It Outgrows?"
              },
              {
                "id": 142384670,
                "url": "https://finnhub.io/api/news?id=10752123b0ed6220b70da01b42cc9bbbaf41f34fe2ef977fbf2d73f9a8670012",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Holding blue-chip Dow dividend payers in a taxable account quietly hands the IRS a cut of every reinvested dollar, year after year, and the compounding cost over two decades is far steeper than most investors expect.",
                "category": "company",
                "datetime": 1790265537,
                "headline": "How a Roth IRA Can Keep Thousands More of Your DJIA Dividend Income Compounding"
              },
              {
                "id": 142379679,
                "url": "https://finnhub.io/api/news?id=47fb0c0d1ea5d7f938146cd3d2cba6f7f12e5e792a65b7020e835a670e3f34b7",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/103332926/image_103332926.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "AMGN",
                "summary": "Novo Nordisk A/S’s 2030 pipeline targets, Wegovy pill growth and Q2 sales show major upside. Click for this NVO stock update.",
                "category": "company",
                "datetime": 1790242799,
                "headline": "Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine"
              },
              {
                "id": 142373835,
                "url": "https://finnhub.io/api/news?id=3621cc74fb7ecfd33c6d6026a7041275fc577f1dbd36f0388640c58ef5c7a82c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "UPLIZNA growth is driven by new indications, global expansion, strong efficacy, differentiated CD19 targeting and twice-yearly dosing, though competition is intensifying.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- \"UPLIZNA Sales Forecast and Market Size Analysis - 2034\" has been added to ResearchAndMarkets.com's offering. The UPLIZNA sales forecast and market analysis report provides a comprehensive assessment of the therapy's commercial outlook across approved and potential autoimmune indication",
                "category": "company",
                "datetime": 1790238840,
                "headline": "UPLIZNA Market Poised for Growth Through 2034 as Expanding Indications and Rising Demand Drive Sales Opportunities"
              },
              {
                "id": 142366657,
                "url": "https://finnhub.io/api/news?id=9d1b6d30a83ac7b25d9c4325db40264db276bc05fde9b5a99294e0ac553350af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen recently reported positive topline Phase 3 OASIZ 301 results for dazodalibep in adults with moderate-to-severe systemic Sjögren’s disease, showing statistically significant and clinically meaningful ESSDAI improvements sustained through Week 48 with generally mild to moderate side effects. Because there are currently no approved disease‑modifying therapies for persistent systemic Sjögren’s, this potential first‑in‑class CD40L antagonist could address an important unmet treatment...",
                "category": "company",
                "datetime": 1790212463,
                "headline": "Amgen (AMGN) Is Up 7.9% After Positive Phase 3 Dazodalibep Data in Systemic Sjögren’s Disease"
              },
              {
                "id": 142364191,
                "url": "https://finnhub.io/api/news?id=4b93f3e764eb31637b2c3af8e26d3fa3252e21c00974f77a07f4e206dd9fbdc5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen Inc (NASDAQ:AMGN, XETRA:AMG)'s price target was raised to $410 from $367 by Jefferies after dazodalibep delivered positive Phase 3 results in patients with systemic Sjögren's disease. Jefferies said the drug, a CD40L antagonist, achieved a statistically significant and clinically...",
                "category": "company",
                "datetime": 1790186040,
                "headline": "Amgen price target raised by Jefferies to $410 after positive Sjögren's data"
              },
              {
                "id": 142384668,
                "url": "https://finnhub.io/api/news?id=83cf5e76682ea04721b804ee005075cdcf4a49a9d6ca480a1a17b1ec5f99cd0d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.",
                "category": "company",
                "datetime": 1790184000,
                "headline": "Viking's Obesity Edge May Be Staying Power, Not Weight Loss"
              },
              {
                "id": 142362607,
                "url": "https://finnhub.io/api/news?id=f9224ce266c05c94437da6790449ec52563bfa7bdaa99cc8a7fdaacf38f9a8a1",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Wednesday.",
                "category": "company",
                "datetime": 1790181609,
                "headline": "Stay informed with the top movers within the dow jones index on Wednesday."
              },
              {
                "id": 142362044,
                "url": "https://finnhub.io/api/news?id=b96034367754f928fd2e584c2fc0028758b681fd889ff1a6c137456348113d8f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.",
                "category": "company",
                "datetime": 1790174280,
                "headline": "AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study"
              },
              {
                "id": 142380020,
                "url": "https://finnhub.io/api/news?id=135b6839d9b72eabc0f4b090e22bdcb8c3730041de5695eff548aa39c400b926",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1790170518,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 142358333,
                "url": "https://finnhub.io/api/news?id=39daa93f12fb1aaac7873cc98266cd588a5e81be0a76291af138bb4bd2206c12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Key Stats for Novo Nordisk StockPrice change for Novo Nordisk stock in last 1 year: -35%$NVO Stock Price as of Sep. 22: $3952-Week High: $64$NVO Stock Price Target: $47What Happened?Novo Nordisk (NVO) stock dropped sharply on Monday after the company laid out new long-term goals that failed to convince investors it can hold its ground against fast-growing rivals in the weight loss drug market.",
                "category": "company",
                "datetime": 1790167286,
                "headline": "Novo Nordisk Stock Slides After Unveiling Long Term Pipeline Growth Targets"
              },
              {
                "id": 142358843,
                "url": "https://finnhub.io/api/news?id=89c11e69e4db005a76127ada782e16f64e9ca8278d764fe2713c3fa77904bc92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Key Stats for Amgen StockPrice change for Amgen stock in last 1 year: 43%$AMGN Stock Price as of Sep. 22: $41052-Week High: $447$AMGN Stock Price Target: $388What Happened?Amgen (AMGN) stock rose after the company shared positive Phase 3 trial results.",
                "category": "company",
                "datetime": 1790166933,
                "headline": "Amgen Stock Gains After Announcing Positive Phase 3 Sjögren’s Disease Trial Results"
              },
              {
                "id": 142356640,
                "url": "https://finnhub.io/api/news?id=d0db740160a2b965b635a57c05836424b88ac56d1b2e2902dfe87a4b0229596b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Veeva Systems (NYSE: VEEV) today announced a new top 20 biopharma commitment, adding to recent selections by Amgen, Biogen, Eli Lilly and Company, and Regeneron. With more than 190 live customers and global commitments from 14 of the top 20 biopharmas, Vault CRM is the next generation of CRM, delivering new agentic and core capabilities to increase field productivity and effectiveness.",
                "category": "company",
                "datetime": 1790161380,
                "headline": "Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva"
              },
              {
                "id": 142343053,
                "url": "https://finnhub.io/api/news?id=2534a90a11e7f38068209ed19a4ad5a1b020c8c9267197b0b92f42964cf80619",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index adding 0.5% and the St",
                "category": "company",
                "datetime": 1790107435,
                "headline": "Sector Update: Healthcare Stocks Rise Late Afternoon"
              },
              {
                "id": 142341737,
                "url": "https://finnhub.io/api/news?id=d1a0fa717a3205c82feb1b910304a2237ef6e5907fe442d635e0bf4fae4efbd3",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Tuesday.",
                "category": "company",
                "datetime": 1790104206,
                "headline": "Tuesday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 142341736,
                "url": "https://finnhub.io/api/news?id=9bb87e258e62e7a642da3a0ac5578e1ec65d5eed0ac4c6bb6207cc2886cc981a",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1790103901,
                "headline": "Discover which S&P500 stocks are making waves on Tuesday."
              },
              {
                "id": 142342103,
                "url": "https://finnhub.io/api/news?id=4d8cd5cd1ebc2815073316cc0a909fc58fe47c0cca0b926bbba7dbf1785ca533",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.",
                "category": "company",
                "datetime": 1790101860,
                "headline": "Amgen reports a Phase 3 win with Sjögren’s drug candidate"
              },
              {
                "id": 142342088,
                "url": "https://finnhub.io/api/news?id=dbc24de1e8390b199f758cca95724b9b2516b2558aa53a5269546e8b16ad10bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "In a trial in patients with Sjögren’s disease, Amgen’s dazodalibep produced a statistically significant and clinically meaningful improvement on a standard score of how the disease affects organs and systems.",
                "category": "company",
                "datetime": 1790100293,
                "headline": "AMGN Jumps After Win In Sjögren’s Disease Trial As Citi Flags ‘Open Questions’"
              },
              {
                "id": 142340992,
                "url": "https://finnhub.io/api/news?id=7f9451e056dd0c45a4304b88f0f9ccd9306f02bc7a8be5192dacae80dd8a134d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Stock Market Today: The Dow Jones index was lower after President Trump threatened Iran at the UN. Apple stock is near a buy point.",
                "category": "company",
                "datetime": 1790098711,
                "headline": "Stock Market Today: Dow Skids As Trump Threatens Iran; Medical Diagnostics Plays Swoon (Live Coverage)"
              },
              {
                "id": 142341145,
                "url": "https://finnhub.io/api/news?id=2d8c31360bae79bdf4e2f1e02084114984ea00c2a14966a1fff9e7886a020981",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NasdaqGS:AMGN) reported positive Phase 3 trial results for dazodalibep in Sjögren's disease, targeting a major unmet autoimmune need. The company described dazodalibep as a potential first-in-class therapy, following successful outcomes in patients with Sjögren's disease. Amgen received an FDA label update for IMDELLTRA in extensive-stage small cell lung cancer, reducing recommended patient monitoring times. The dazodalibep Phase 3 success and IMDELLTRA monitoring change both reshape...",
                "category": "company",
                "datetime": 1790097189,
                "headline": "Amgen (AMGN) Posted Positive Phase 3 Results In Sjögren's Disease"
              },
              {
                "id": 142340388,
                "url": "https://finnhub.io/api/news?id=f2b585db9bcaae9e84130e615a8e8ef41261f486b04f1b7c75b84e8417f50f6d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.",
                "category": "company",
                "datetime": 1790094901,
                "headline": "These S&P500 stocks are moving in today's session"
              },
              {
                "id": 142339778,
                "url": "https://finnhub.io/api/news?id=778740497b3c831a1941f86fb750b8a36ba481502a5f4ea9afedca9d14084e84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Stock Market Today: The Dow Jones index reversed lower despite new U.S.-Iran peace hopes. Apple stock is trading near a buy point.",
                "category": "company",
                "datetime": 1790090548,
                "headline": "Stock Market Today: Dow Slips But Apple Touches A Buy Point; Homebuilder, Retailer Funds Shine (Live Coverage)"
              },
              {
                "id": 142339971,
                "url": "https://finnhub.io/api/news?id=ba1c67b62a75b47784e3e11b005f153ce9a76e466963c2fe8f76b062f1a38797",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment.",
                "category": "company",
                "datetime": 1790089807,
                "headline": "Amgen Boasts Success In Sjogren's; Shares Charge Ahead"
              },
              {
                "id": 142360738,
                "url": "https://finnhub.io/api/news?id=f7dbf71da8f4ca654a7a528ca19e2ce31abe947c86801df595990ffe35367f82",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/22/Amgen-Inc--NASDAQ-AMGN.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Amgen's Phase 3 study shows dazodalibep significantly improves systemic disease activity in adults with Sjögren's disease.",
                "category": "company",
                "datetime": 1790085379,
                "headline": "Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data"
              },
              {
                "id": 142337779,
                "url": "https://finnhub.io/api/news?id=92e0e0c1543d7f89dd5d7edd4324186ec9bde19b1453d2d539e2f9cbcca61a62",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) today announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity.",
                "category": "company",
                "datetime": 1790082000,
                "headline": "AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE"
              },
              {
                "id": 142339225,
                "url": "https://finnhub.io/api/news?id=9b645c85ddc4b85f2b0779a66606c423cecbb91dccf298b9743d1cb81b4939c6",
                "image": "",
                "source": "Benzinga",
                "related": "AMGN",
                "summary": "Amgen (NASDAQ:AMGN) today announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity.The study met",
                "category": "company",
                "datetime": 1790067744,
                "headline": "Amgen Announces Its Phase 3 OASIZ 301 Trial Of Dazodalibep To Treat Sjogren's Disease Meets Primary Endpoint, Shows Improvement In Systemic Disease Activity At Week 48"
              },
              {
                "id": 142328954,
                "url": "https://finnhub.io/api/news?id=2fca840fa5a15f836510ef755299156fdc47f9fb2b7ced05416b2ea688c1b0a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Site-specific PEGylation is enabling safer, longer-acting biologics, while demand in chronic disease, targeted therapies and biosimilars creates opportunities for services and reagents.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- \"PEGylated Proteins - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering.The global market for PEGylated Proteins was estimated at US$2.0 Billion in 2025 and is projected to reach US$4.1 Billion by 2032, growing at a CAGR of 10.6% from 2",
                "category": "company",
                "datetime": 1790065680,
                "headline": "Capitalize on the PEGylated Proteins Revenue Shift: Benchmark Amgen, Roche, Merck KGaA, Pfizer and Novo Nordisk to Secure Competitive ROI Through the Forecast Period"
              },
              {
                "id": 142340644,
                "url": "https://finnhub.io/api/news?id=033972e3854745199d16a43e53d2bfecd4f709597d776ba31ba77bbd14999b14",
                "image": "https://image.cnbcfm.com/api/v1/image/108264668-1770841844066-gettyimages-2260574499-DOUSTDAR_INTERVIEW.jpeg?v=1770841930&w=1920&h=1080",
                "source": "CNBC",
                "related": "AMGN",
                "summary": "Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.",
                "category": "company",
                "datetime": 1790052809,
                "headline": "Novo defends diversification push as CEO eyes deals beyond obesity"
              },
              {
                "id": 142319419,
                "url": "https://finnhub.io/api/news?id=6aab39f1ba9b99aa3774a4630738430f5d3d0c074278865a0844d6a32ac10df5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "A private meeting with Amgen management left Morgan Stanley with a very different read than the broader market’s.",
                "category": "company",
                "datetime": 1790046420,
                "headline": "Morgan Stanley flags Amgen's edge after heart-drug rival stumbles"
              },
              {
                "id": 142314744,
                "url": "https://finnhub.io/api/news?id=e6496cc7db7e9111a7897039f2f9c4ff5bdbd27f5ce1e995c0fa5a03fabb7ff1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The Dow Jones index rallies on the stock market today after Treasury Secretary Scott Bessent touts China talks. Nvidia stock climbs.",
                "category": "company",
                "datetime": 1790022710,
                "headline": "Stock Market Today: Dow Up, Nasdaq Roars As Micron Tests Entry; Bessent Touts China Progress (Live Coverage)"
              },
              {
                "id": 142315103,
                "url": "https://finnhub.io/api/news?id=b53529fb4b4e50f832281391ee6152c1bd95ce2d1b0a9963b6ed300a46036f95",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "The Dow Jones index rallies on the stock market today after Treasury Secretary Scott Bessent touts China talks. Nvidia stock climbs.",
                "category": "company",
                "datetime": 1790019499,
                "headline": "Stock Market Today: Nasdaq Roars As Micron Tests Entry; AMD In Buy Zone As It Eyes New High (Live Coverage)"
              },
              {
                "id": 142314885,
                "url": "https://finnhub.io/api/news?id=6b60aafe19039b5cca9e0c65ac7a387241ec14975ff4c78415c03412b39755ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "VEEV expands its decade-long Amgen partnership with a global Vault CRM rollout, reinforcing enterprise adoption and commercial subscription growth.",
                "category": "company",
                "datetime": 1790010240,
                "headline": "Veeva Expands Amgen Partnership With Global Vault CRM Rollout Plan"
              },
              {
                "id": 142314740,
                "url": "https://finnhub.io/api/news?id=14e4cf65769e673f42a4d4281a5372e23d98a76970930436984c66e0099204fa",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "AMGN",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Monday.",
                "category": "company",
                "datetime": 1790008805,
                "headline": "Discover which dow jones stocks are making waves on Monday."
              },
              {
                "id": 142314602,
                "url": "https://finnhub.io/api/news?id=df358dd889b74f0f3a7960fb05b1d7e8799ab3a84e386622f4f19c8e1fe5455c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.",
                "category": "company",
                "datetime": 1790006580,
                "headline": "Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate"
              },
              {
                "id": 142314828,
                "url": "https://finnhub.io/api/news?id=90b2da6f1c010ca0c0afbc6e0da4e706ef8d938405a2b7b029e85696882d9e2d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Novo Nordisk (NYSE:NVO), the Danish drugmaker, saw its US-listed shares fall over 7% to $39.82 on Monday after new long-term targets failed to ease investor concerns about competition in the weight-loss drug market. The company said it aims to launch more than five multi-blockbuster drugs by...",
                "category": "company",
                "datetime": 1790006100,
                "headline": "Novo Nordisk shares plunge over 7% as new targets fail to reassure investors"
              },
              {
                "id": 142314197,
                "url": "https://finnhub.io/api/news?id=cd03e6c221c2ad3503ecfdfcb6bec072eee1fc5a7269bc57244a37a3ea21e6d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "Stock Market Today: The Dow Jones index rallies Monday as oil prices and Treasury yields drop. Nvidia and Google stock climb.",
                "category": "company",
                "datetime": 1790003266,
                "headline": "Stock Market Today: Dow Up As Alphabet Shines, Tech Fund Offers Entry; Oil Dips On Iran Hopes (Live Coverage)"
              },
              {
                "id": 142311933,
                "url": "https://finnhub.io/api/news?id=41c22a61c585fb8ea717f46507a954c1ebf2e56ee928929360354fd9842082d6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "AMGN",
                "summary": "AMD's AI infrastructure demand is broadening as EPYC CPUs and Instinct accelerators gain traction, while Helios ramps and multigigawatt commitments boost visibility.",
                "category": "company",
                "datetime": 1789995600,
                "headline": "The Zacks Analyst Blog Highlights AMD, Linde, Amgen and INNOVATE"
              },
              {
                "id": 142340649,
                "url": "https://finnhub.io/api/news?id=2059a9ef57dbfa8b8e82f89f3b9878fe009b8717089366ff4944c7fa9b32ff70",
                "image": "https://image.cnbcfm.com/api/v1/image/108363158-17894901612026-09-15t163359z_2080430281_rc2qjna3z3zx_rtrmadp_0_novo-nordisk-strategy-townhall.jpeg?v=1789490250&w=1920&h=1080",
                "source": "CNBC",
                "related": "AMGN",
                "summary": "The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.",
                "category": "company",
                "datetime": 1789964630,
                "headline": "Novo shares slide as drugmaker lays out post-Wegovy growth strategy"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.3,
            "source_article_count": 176,
            "discarded_article_count": 153
          },
          "sentimentPoints": 3
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 23.2,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1,
            "vcp_reason": "跌縮量(近10日4日)；站上MA50；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 3140013.3333333335,
              "down_days": 4,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 2619770,
              "avg_vol_20": 2818920,
              "avg_vol_30": 3140013.3333333335,
              "range_pct_10": 0.10422836834191461,
              "range_pct_20": 0.10422836834191461,
              "range_pct_30": 0.15332396227274803,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.834318113298882,
              "dist_to_20d_high": 0.006383579174584012,
              "down_shrink_days": 4,
              "breakout_level_20d": 441.76001,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.6797917742074963
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 4,
          "volumeWeight": 2,
          "maCrossPoints": 3.2,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.538752449081879,
              "turnoverUsdM": 940.0887715,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.8,
          "stopLevels": {
            "symbol": "US.AMGN",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 416.6528,
            "strength_details": {
              "ma_score": 3,
              "atr_score": 2,
              "rsi_score": 2,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.7,
            "stop_loss_percent": 5.1,
            "take_profit_price": 475.7139,
            "target_multiplier": 2.2,
            "technical_strength": 2.25,
            "take_profit_percent": 8.4
          },
          "positionPoints": 1.6,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.654355863455257,
          "stopLossPercent": 5.077504898163758,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 11.1436,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.54
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 139.56
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0052
    },
    "kdj": {
      "d": 71.97,
      "j": 90.61,
      "k": 78.18,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 44.34
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 8280025,
      "recentSlope": 417122.5,
      "previousSlope": -570030
    },
    "rsi": 59.25,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 424.2295,
      "position": "SAR喺價下",
      "distancePct": 3.35,
      "previousTrend": "上升"
    },
    "ma50": 415.7288,
    "macd": {
      "macd": 6.336632099115491,
      "trend": "強烈看漲",
      "signal": 3.4140032927059583,
      "histogram": 2.9226288064095325
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 416.8905,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 21
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.78,
      "score": 2,
      "avgVolume": 2739991,
      "currentVolume": 2141725
    },
    "derived": {
      "ma20": 416.411,
      "ma50": 415.7288,
      "prevClose": 424.94,
      "avgVolume10": 2630293,
      "avgVolume20": 2739991,
      "changePercent": 3.29,
      "avgVolumeForScore": 2739991
    },
    "ma_cross": {
      "ma20": 416.411,
      "ma50": 415.7288,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "上穿",
      "score": 8,
      "prevMa20": 414.976,
      "prevMa50": 415.294,
      "spreadPct": 0.16,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 395.041,
      "upper": 437.781,
      "position": "上半部"
    },
    "rsi_short": 71.8,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.78
    }
  }
}

{
  "close": 438.94,
  "volume": 2141725,
  "changePercent": 3.29
}